Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;79(2):139-159.
doi: 10.1111/his.14328. Epub 2021 May 6.

Delineating the breast cancer immune microenvironment in the era of multiplex immunohistochemistry/immunofluorescence

Affiliations
Review

Delineating the breast cancer immune microenvironment in the era of multiplex immunohistochemistry/immunofluorescence

Tracy Z Tien et al. Histopathology. 2021 Aug.

Abstract

Breast cancer is the most common malignancy and the leading cause of cancer death in females worldwide. Treatment is challenging, especially for those who are triple-negative. Increasing evidence suggests that diverse immune populations are present in the breast tumour microenvironment, which opens up avenues for personalised drug targets. Historically, our investigations into the immune constitution of breast tumours have been restricted to analyses of one or two markers at a given time. Recent technological advances have allowed simultaneous labelling of more than 35 markers and detailed profiling of tumour-immune infiltrates at the single-cell level, as well as determining the cellular composition and spatial analysis of the entire tumour architecture. In this review, we describe emerging technologies that have contributed to the field of breast cancer diagnosis, and discuss how to interpret the vast data sets obtained in order to effectively translate them for clinically relevant use.

Keywords: TILs; breast cancer; digital pathology; immunohistochemistry; immunotherapy; multiplex imaging; pathology; tumour microenvironment; tumour-infiltrating lymphocytes.

PubMed Disclaimer

References

    1. Melichar B, Študentová H, Kalábová H et al. Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy. Anticancer Res. 2014; 34; 1115-1125.
    1. Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J. Immunother. Cancer 2016; 4; 59.
    1. Galon J, Mlecnik B, Bindea G et al. Towards the introduction of the ‘immunoscore’ in the classification of malignant tumours. J. Pathol. 2014; 232; 199-209.
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018; 68; 394-424.
    1. Denkert C, Loibl S, Noske A et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 2009; 28; 105-113.

MeSH terms

Substances

LinkOut - more resources